Regeneus announces positive results from its cancer vaccine trial
Health & Biotech
Health & Biotech
Link copied to
Special report: Shares in regenerative medicine company Regeneus jumped 15 per cent after positive results from the company’s Phase I trial of its cancer vaccine.
The stock (ASX:RGS) hit an intraday high of 27c up from 23.5c on Friday.
The company is testing its cancer therapy RGSH4K, a vaccine manufactured from a patient’s own cancer cells.
These types of vaccines, called autologous vaccines, offer patients more specific, personalised treatment with the right mix of tumour associated antigens (TAAs) for the body to recognise and attack.
The study, known as the ACTIVATE trial, is evaluating the safety and tolerability of the vaccine and to identify the right dosage to take into future trials.
Regeneus told investors today that all dose levels were safe and well-tolerated by patients, with no serious adverse effects to the vaccine.
The company also said some patients also showed signs of immune stimulation, as demonstrated by changes in cancer markers, immune cells and cytokines.
Preliminary indications of anti-tumour activity were also seen in some patients, however the company is following up on half of the patients involved.
Professor Stephen Clarke, a leading oncologist and one of the Principal Investigators for the trial was buoyed by the results.
“The immune response, including favourable changes in biomarkers, coupled with the benign safety profile for RGSH4K, encourages proceeding to further clinical evaluation,” said Clarke.
Regeneus head John Martin said the data advances the company’s clinical development.
“Data obtained from this first-in-human clinical study is encouraging and highlights the clinical potential of RGSH4K.”
“We’re pleased with the results and will use them to advance both further studies and our partnering discussions with interested parties.”
This special report is brought to you by Regeneus.
This advice has been prepared without taking into account your objectives, financial situation or needs. You should, therefore, consider the appropriateness of the advice, in light of your own objectives, financial situation or needs, before acting on the advice.
If this advice relates to the acquisition, or possible acquisition, of a particular financial product, the recipient should obtain a disclosure document, a Product Disclosure Statement or an offer document (PDS) relating to the product and consider the PDS before making any decision about whether to acquire the product.